1.
Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN estimates
of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin 2018; 68: 394-424.
2.
Tveit KM, Guldvog I, Hagen S et al. Randomized controlled trial of postoperative radiotherapy
and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment
of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br
J Surg 1997; 84: 1130-1135.
3.
Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy
for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
4.
Roh MS, Colangelo LH, O'Connell MJ et al. Preoperative multimodality therapy improves
disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin
Oncol 2009; 27: 5124-5130.
5.
Ngwa W, Irabor OC, Schoenfeld JD et al. Using immunotherapy to boost the abscopal
effect. Nat Rev Cancer 2018; 18: 313-322.
6.
Ceze N, Thibault G, Goujon G et al. Pre-treatment lymphopenia as a prognostic biomarker
in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011;
68: 1305-1313.
7.
Kitayama J, Yasuda K, Kawai K et al. Circulating lymphocyte is an important determinant
of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer
2011; 11: 64.
8.
Heo J, Chun M, Noh OK et al. Sustaining Blood Lymphocyte Count during Preoperative
Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally
Advanced Rectal Cancer. Cancer Res Treat 2016; 48: 232-239.
9.
Tang C, Liao Z, Gomez D et al. Lymphopenia association with gross tumor volume and
lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat
Oncol Biol Phys 2014; 89: 1084-1091.
10.
Davuluri R, Jiang W, Fang P et al. Lymphocyte Nadir and Esophageal Cancer Survival
Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2017; 99: 128-135.
11.
Choi CH, Kang H, Kim WY et al. Prognostic value of baseline lymphocyte count in cervical
carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008;
71: 199-204.
12.
Peng LC, Milsom J, Garrett K et al. Surveillance, epidemiology, and end results-based
analysis of the impact of preoperative or postoperative radiotherapy on survival outcomes
for T3N0 rectal cancer. Cancer Epidemiol 2014; 38: 73-78.
13.
Cho O, Oh YT, Chun M et al. Radiation-related lymphopenia as a new prognostic factor
in limited-stage small cell lung cancer. Tumour Biol 2016; 37: 971-978.
14.
Balmanoukian A, Ye X, Herman J et al. The association between treatment-related lymphopenia
and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.
Cancer Invest 2012; 30: 571-576.
15.
Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients
with stage III non-small-cell lung cancer. Cancer Invest 2013; 31: 183-188.
16.
Wild AT, Ye X, Ellsworth SG et al. The Association Between Chemoradiation-related
Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.
Am J Clin Oncol 2015; 38: 259-265.
17.
Campian JL, Sarai G, Ye X et al. Association between severe treatment-related lymphopenia
and progression-free survival in patients with newly diagnosed squamous cell head
and neck cancer. Head Neck 2014; 36: 1747-1753.
18.
Wild AT, Herman JM, Dholakia AS et al. Lymphocyte-Sparing Effect of Stereotactic Body
Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Int J Radiat Oncol
Biol Phys 2016; 94: 571-579.
19.
Hari DM, Leung AM, Lee JH et al. AJCC Cancer Staging Manual 7th edition criteria for
colon cancer: do the complex modifications improve prognostic assessment? J Am Coll
Surg 2013; 217: 181-190.